Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Creatine lawsuit

This article was originally published in The Tan Sheet

Executive Summary

Muscle Marketing USA, which distributes Creatine Serum, files $150 mil. lawsuit July 3 against Degussa Bioactives for unlawful and unfair business practices, false advertising and unlawful concealment of facts relating to the firm's Creapure powder. MMUSA alleges Degussa's ads misrepresent facts about creatine by telling consumers Creapure is safe, "even though it is associated with ailments ranging from stomach cramps to dehydration." Firm further contends that since 1999, Degussa "has repeatedly attempted to misappropriate information about the chemical formulation and nature of Creatine Serum," which is a liquid form of creatine marketed to athletes. 1MMUSA's Web site maintains Creatine Serum is safer than powders because small doses "have the equivalent benefits of large amounts of powder"...

You may also be interested in...

GNC creatine serum

Muscle Marketing USA objects to GNC marketing "shoddy imitation" of its Creatine Serum that "does not contain creatine phosphate complex" or absorb as easily into the body. In an Aug. 4 release, the Los Angeles-based firm insists GNC either rename the copycat product "or face legal action." GNC has agreed to change the name of its creatine product "as soon as their current inventory is exhausted," MMUSA reports. The firm filed a $150 mil. lawsuit against Degussa Bioactives for falsely advertising the safety of its Creapure creatine powder in July (1"The Tan Sheet" July 7, 2003, In Brief)....

The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.

Mallinckrodt's Opioid Resolution Through Generic Unit Bankruptcy May Be 'Test Case'

Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts